Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

With the rapid advances of various high-throughput technologies, generation of '-omics' data
is commonplace in almost every biomedical field. Effective data management and analytical …

Purpose: Patients with hormone receptor–negative breast cancer generally do not benefit
from endocrine-targeted therapies. However, a subset with androgen receptor (AR) …

Androgen receptor (AR) signaling exerts an antiestrogenic, growth-inhibitory influence in
normal breast tissue, and this role may be sustained in estrogen receptor α (ERα)-positive …

Breast cancer is a heterogeneous disease and several distinct subtypes exist based on
differential gene expression patterns. Molecular apocrine tumours were recently identified …

The antibody response magnitude and kinetics may impact clinical severity, serological
diagnosis and long-term protection of COVID-19, which may play a role in why children …

Background The objective of the study was to evaluate the implications of androgen receptor
(AR) in breast cancers. Patients and methods We investigated immunohistochemical AR …

Introduction: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3
immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also …

Animal models of cancer have been instrumental in advancing our understanding of the
biology of tumor initiation and progression, in studying gene function and in performing …

Androgen receptor (AR, a member of the steroid hormone receptor family) status has
become increasingly important as both a prognostic marker and potential therapeutic target …